Position in CLDX
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$186,384
+$185,496 QoQ
Shares Held
5,009
+15078.8% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#185
of 252 holders
Holding Since
Dec 2021
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CLDX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MEEDER ASSET MANAGEMENT INC holds $6,351,882 across 34 Biotechnology names. CLDX ranks #4 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
7,156 | $4,462,048 | |
| 2 | CAI |
Caris Life Sciences, Inc.
|
34,035 | $606,501 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,570 | $472,613 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
This page
|
5,009 | $186,384 | |
| 5 | MNPR |
Monopar Therapeutics
|
1,389 | $128,607 | |
| 6 | RAPP |
Rapport Therapeutics, Inc.
|
2,774 | $115,592 | |
| 7 | CRVS |
Corvus Pharmaceuticals, Inc.
|
6,055 | $90,461 | |
| 8 | ADMA |
Adma Biologics, Inc.
|
8,913 | $74,601 |
All Filings in CLDX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $186,384 | 5,009 | Shares | Sole | 2026-08-07 | |
| 2022-06-30 | $888 | 33 | Shares | Defined | 2022-08-08 | |
| 2022-03-31 | $1,123 | 33 | Shares | Defined | 2022-05-10 | |
| 2021-12-31 | $1,274 | 33 | Shares | Defined | 2022-02-11 | |
| No filing history on record for this holder in this stock. | ||||||